Research
Hormonal
Obesity and metabolic syndrome worsen the clinical outcomes of HCC, including higher rates of microvascular invasion, tumor recurrence, and mortality, potentially mediated by adipokines like leptin promoting angiogenesis.
If you have HCC and are obese or diabetic, your risk of the cancer coming back or spreading is higher. This is partly due to biological factors like increased blood vessel growth in tumors. Managing your metabolic health is part of your cancer care plan.
ModerateSupportsMEDIUM confidence
These correlations suggest a possible association between the metabolic syndrome and worsened clinical outcomes that may be mediated by adipokines, which lead to increased vascular invasion.
Why this rating
Based on retrospective analyses and animal models; human prospective data on outcomes is less robust than incidence data.
Source
Metabolic syndrome and hepatocellular carcinoma
Abby B. Siegel et al. · Cancer · 2009
DOI 10.1002/cncr.24687
narrative_reviewCited 389×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →